Feature

How Often Should We Test for Hepatitis C in People Who Inject Drugs?

A major challenge associated with hepatitis screening is the loss to follow-up that occurs in people who inject drugs.

Toward Integrated Care for Hepatitis C Infection and Addiction

There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.

Clinical Significance of the Isolated Anti-HBc Serologic Pattern

A serological pattern called isolated anti-HBc, characterized by the presence of hepatitis B core antibody (anti-HBc) and the absence of hepatitis B surface antigen and ...

Point-Counterpoint: Should We Implement Needle Exchange Programs for the Prevention of Hepatitis C Virus?

Of the approximately 12.7 to 16 million people who inject drugs (PWID) worldwide, an estimated 10 million individuals have hepatitis C virus (HCV), making it ...

Can Direct-Acting Antivirals Finally Achieve Hepatitis C Elimination?

Unrestricted use of DAAs may be an invaluable component of preventing HCV transmission by reducing the infectious pool of individuals.

Etiology of Acute Liver Failure Can Yield Surprising Findings

Before the advent of potent antiviral agents, liver transplantation was the only treatment option for patients with hepatitis and a poor prognosis; antiretrovirals can now ...

Addressing Palliative Care in Hepatocellular Carcinoma

Research shows that palliative care can help with symptom management, care coordination, therapeutic decision making, and the psychosocial aspects of living with hepatocellular carcinoma.

Biologic Psoriasis Therapies Pose Limited Risk for Hepatitis B Reactivation

In patients with psoriasis who were previously exposed to HBV or who have chronic HBV, immunosuppressive therapies can cause viral reactivation, although the risk is ...

News Articles

Subgroup-Specific Differences in Amino Acid Composition Identified in Chronic Hepatitis B

Subgroup-Specific Differences in Amino Acid Composition Identified in Chronic Hepatitis B

Sequence Harmony was used to identify common sites between the subgroups of HBeAg status and between those with response and non-response to therapy.

Detectable HCV RNA at End of Treatment May Not Influence SVR Rates

Detectable HCV RNA at End of Treatment May Not Influence SVR Rates

Detectable hepatitis C virus RNA results are noted to occur even if highly sensitive hepatitis C virus RNA assays are used.

How Often Should We Test for Hepatitis C in People Who Inject Drugs?

How Often Should We Test for Hepatitis C in People Who Inject Drugs?

A major challenge associated with hepatitis screening is the loss to follow-up that occurs in people who inject drugs.

Factors Associated With Faster Time to Hepatitis C Treatment

Factors Associated With Faster Time to Hepatitis C Treatment

The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.

Journal Articles

Sign Up for Free e-newsletters